<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124433</url>
  </required_header>
  <id_info>
    <org_study_id>ARN509 - 2016</org_study_id>
    <nct_id>NCT03124433</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer</brief_title>
  <official_title>Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in the Treatment of Intermediate to High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated phase II single arm trial, combining neoadjuvant&#xD;
      apalutamide (ARN509) with radical prostatectomy, in the treatment of D'Amico intermediate to&#xD;
      high risk organ-confined prostate cancer. Apalutamide has shown efficacy in castrate&#xD;
      resistant prostate cancer in phase II studies and are now in phase III trials combined with&#xD;
      radiation in organ confined disease.&#xD;
&#xD;
      The primary study objectives include assessment of (i) oncological efficacy as determined by&#xD;
      tumour downstaging and achievement of nadir PSA The secondary study objectives include(i)&#xD;
      determination of adverse effects related to apalutamide and surgical complication rates (ii)&#xD;
      human prostate tissue effect of apalutamide&#xD;
&#xD;
      The study will recruit thirty eligible participants who will receive 12 weeks of oral&#xD;
      apalutamide 240mg daily. This will be followed by standard-of-care radical prostatectomy. The&#xD;
      total trial duration is 26 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II single arm study looking at the efficacy of 12 weeks of neoadjuvant&#xD;
      apalutamide (ARN 509), combined with standard-of-care radical prostatectomy, for D'Amico&#xD;
      intermediate to high risk prostate cancer patients. The phases of the study will include:&#xD;
      screening, treatment and follow-up phases.&#xD;
&#xD;
      Safety will be monitored throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Actual">August 22, 2019</completion_date>
  <primary_completion_date type="Actual">August 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with pathological downstaging after neodjuvant apalutamide followed by radical prostatectomy</measure>
    <time_frame>24 weeks</time_frame>
    <description>This is described as residual cancer burden and treatment response group on histopathology after neoadjuvant apalutamide and radical prostatectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with biochemical treatment response following neoadjuvant apalutamide and radical prostatectomy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patients who attain serum PSA levels below 0.03microg/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who report significant adverse effects after 12 weeks of neoadjuvant apalutamide</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse effects as defined by CTCAE criteria grade 3 and above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with peri-operative complications following neoadjuvant apalutamide and radical prostatectomy</measure>
    <time_frame>24 weeks</time_frame>
    <description>The level of complications defined by Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cancer of the Prostate</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant apalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Participants will receive oral apalutamide 240mg daily for 12 weeks</description>
    <arm_group_label>Neoadjuvant apalutamide</arm_group_label>
    <other_name>ARN509</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically diagnosed primary adenocarcinoma of the prostate gland&#xD;
&#xD;
          -  non-metastatic D'Amico intermediate to high risk patients undergoing radical&#xD;
             prostatectomy as primary definitive therapy&#xD;
&#xD;
          -  no known hypersensitivity to the study drug&#xD;
&#xD;
          -  able to swallow study drug as whole tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of small cell, neuroendocrine or ductal differentiation at needle biopsy&#xD;
&#xD;
          -  individuals with prior pelvic irradiation therapy for any form of pelvic malignancy&#xD;
&#xD;
          -  patients with psychiatric conditions requiring anti-psychotic therapy, or preventing&#xD;
             the provision of informed consent&#xD;
&#xD;
          -  renal impairment with serum creatinine more than twice the upper limit of normal&#xD;
&#xD;
          -  Other prior malignancy less than or equal to 5 years prior to recruitment&#xD;
&#xD;
          -  ECOG performance status 2 or poorer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lui Shiong Lee, MBBS,MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>prostatectomy, retropubic</keyword>
  <keyword>Androgen Receptor Antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

